论文部分内容阅读
目的:探讨多发性骨髓瘤(MM)患者血清乳酸脱氢酶(LDH)和β2-微球蛋白(β2-MG)测定的临床意义。方法:分别采用速率法和放免法测定49例MM患者血清LDH和β2-MG值。结果:对照组与MM组、MM组的Ⅲ期与Ⅱ期、Ⅱ期与Ⅰ期、MM组化疗前后有效与无效患者血清LDH和β2-MG值相比,MM组明显高于对照组,差异有显著性(P<0.05),而无效组化疗前后差异无统计学意义(P>0.05)。结论:血清LDH和β2-MG的水平可作为MM患者的分期、预后及疗效判断的辅助指标。
Objective: To investigate the clinical significance of serum lactate dehydrogenase (LDH) and β2-microglobulin (β2-MG) in patients with multiple myeloma (MM). Methods: Serum LDH and β2-MG levels were measured in 49 MM patients by rate method and radioimmunoassay respectively. Results: The levels of LDH and β2-MG in MM group, MM group in stage Ⅲ and Ⅱ, Ⅱ and Ⅰ, MM group before and after chemotherapy were significantly higher in MM group than in control group, the difference (P <0.05), while there was no significant difference between the two groups (P> 0.05). Conclusion: The levels of serum LDH and β2-MG can be used as auxiliary indicators for staging, prognosis and curative effect in patients with MM.